IGM Biosciences, Inc. IGMS
Set alert
1.27 0.00 0.00%
At close · Aug 14
1.27 Day range 1.27
6.15 52-week range 22.50
- YTD
- -79.21%
- 1 year
- -85.70%
- Open
- 1.27
- Prev close
- 1.27
- Mkt cap
- 387.11M
- Vol
- 1.59M
- Avg vol
- 268.09K
- EPS
- -3.61
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.27
- High
- 1.27
- Forward P/E
- -2.71
- Beta
- 0.19
- Short ratio
- 11.22
- Inst. own
- 63.97%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 12.15
- 200-d avg
- 10.57
- 1y target
- 19.73
3M chart
Signals (14)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Jul 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 2, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| SMA: Bearish | Jun 12, 2025 | 1 year ago |
| SMA: Bearish | Jun 12, 2025 | 1 year ago |
| SMA: Bullish | May 29, 2025 | 1 year ago |
| SMA: Bullish | May 23, 2025 | 1 year ago |
| SMA: Bearish | May 21, 2025 | 1 year ago |
| SMA: Bearish | May 21, 2025 | 1 year ago |
| MACD: Buy Signal | May 20, 2025 | 1 year ago |
| SMA: Bullish | May 19, 2025 | 1 year ago |
| SMA: Bullish | May 19, 2025 | 1 year ago |
Key statistics
- Market cap
- 387.11M
- Enterprise value
- 237.37M
- Trailing P/E
- 0.00
- Forward P/E
- -2.71
- PEG ratio
- 0.00
- Price / sales
- 132.66
- Price / book
- 4.90
- EPS (TTM)
- -3.61
- Beta
- 0.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.92M
- Revenue growth
- 1.40%
- Free cash flow
- -100.20M
- Total cash
- 218.79M
- Total debt
- 45.86M
- Return on equity
- -132.11%
- Shares outstanding
- 34.08M
- Short % of float
- 17.77%
- 50-day average
- 12.15
- 200-day average
- 10.57
Analyst view
Consensus: buy
Buy
Price target (mean) 19.73 +1453.3% upside
Now 1.27
- Target (low)
- 9.00
- Target (mean)
- 19.73
- Target (high)
- 48.00
Ratings (0m) 11 6 buy · 4 hold · 1 sell
- Strong buy2
- Buy4
- Hold4
- Sell0
- Strong sell1
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.785.
Financials — quick view
IGMS Revenue — quarterly 143.62M
IGMS Net income — quarterly 97.58M
IGMS EPS — quarterly 1.59
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.82 | -1.01 | -0.19 | -23.17% |
| Aug 14, 2024 | Jun 1, 2024 | 0.03 | -0.79 | -0.82 | -2,733.33% |
| Aug 14, 2024 | Jun 1, 2024 | 0.03 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.84 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.84 | -0.83 | +0.01 | +1.19% |
| Mar 7, 2024 | Dec 1, 2023 | -1.06 | -1.01 | +0.05 | +4.72% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | BMO Capital | init | — | Outperform |
| Nov 11, 2024 | Stifel | main | Buy | Buy |
| Oct 18, 2024 | RBC Capital | main | Outperform | Outperform |
| Oct 1, 2024 | Guggenheim | main | Buy | Buy |
| Oct 1, 2024 | Wedbush | main | Outperform | Outperform |
| Oct 1, 2024 | RBC Capital | main | Outperform | Outperform |
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- igmbio.com
News
- IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
- IGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders
- IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
- IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
- IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
Your note
Sign in to keep a note on IGMS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Sep 29, 2024 | 0 |
| BEHRENS M KATHLEEN | Director | Stock Award(Grant) | Sep 29, 2024 | 406,515 |
| DECKER LISA LYNN | Officer | Sale | Dec 15, 2024 | 78,041 |
| HARLER MARY BETH | Chief Executive Officer | Sale | Dec 15, 2024 | 347,032 |
| LEE MICHAEL STEWART | Director | Stock Award(Grant) | Sep 29, 2024 | 9,322 |
| REDMILE GROUP, L.L.C. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Sep 29, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 12.01% | 4,092,310 | 26.64M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 11.78% | 4,014,259 | 26.13M | Sep 29, 2024 |
| Siren, L.L.C. | 9.77% | 3,330,422 | 21.68M | Sep 29, 2024 |
| Redmile Group, LLC | 9.02% | 3,072,478 | 20.00M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 3.70% | 1,259,230 | 8.20M | Sep 29, 2024 |
| Blackrock Inc. | 2.64% | 899,921 | 5.86M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 5.77% | 1,966,446 | 12.80M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 2.49% | 849,754 | 5.53M | Sep 29, 2024 |
| Fidelity Select Portfolios - Biotechnology | 2.38% | 809,982 | 5.27M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.35% | 461,049 | 3.00M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.18% | 401,289 | 2.61M | Oct 30, 2024 |
| Price (T.Rowe) New Horizons Trust | 1.16% | 396,148 | 2.58M | Sep 29, 2024 |